DE69834179T2 - Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. - Google Patents

Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. Download PDF

Info

Publication number
DE69834179T2
DE69834179T2 DE69834179T DE69834179T DE69834179T2 DE 69834179 T2 DE69834179 T2 DE 69834179T2 DE 69834179 T DE69834179 T DE 69834179T DE 69834179 T DE69834179 T DE 69834179T DE 69834179 T2 DE69834179 T2 DE 69834179T2
Authority
DE
Germany
Prior art keywords
protein
virus
chemokines
cells
chemokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834179T
Other languages
German (de)
English (en)
Other versions
DE69834179D1 (de
Inventor
Universtiy of Oxford Geoffrey SMITH
Universtiy of Oxford Aylwin NG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxxon Therapeutics Ltd
Original Assignee
Oxxon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703592.7A external-priority patent/GB9703592D0/en
Priority claimed from GBGB9800113.4A external-priority patent/GB9800113D0/en
Application filed by Oxxon Therapeutics Ltd filed Critical Oxxon Therapeutics Ltd
Publication of DE69834179D1 publication Critical patent/DE69834179D1/de
Application granted granted Critical
Publication of DE69834179T2 publication Critical patent/DE69834179T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69834179T 1997-02-21 1998-02-23 Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. Expired - Fee Related DE69834179T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9703592.7A GB9703592D0 (en) 1997-02-21 1997-02-21 Poxvirus chemokine-binding protein
GB9703592 1997-02-21
GB9800113 1998-01-05
GBGB9800113.4A GB9800113D0 (en) 1998-01-05 1998-01-05 A soluble vaccinia virus protein that binds chemokines
PCT/GB1998/000569 WO1998037217A1 (en) 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines

Publications (2)

Publication Number Publication Date
DE69834179D1 DE69834179D1 (de) 2006-05-24
DE69834179T2 true DE69834179T2 (de) 2007-02-01

Family

ID=26311039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834179T Expired - Fee Related DE69834179T2 (de) 1997-02-21 1998-02-23 Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.

Country Status (7)

Country Link
US (3) US6355252B1 (enExample)
EP (2) EP1405916A1 (enExample)
JP (1) JP4191255B2 (enExample)
AT (1) ATE323170T1 (enExample)
AU (1) AU749921B2 (enExample)
DE (1) DE69834179T2 (enExample)
WO (1) WO1998037217A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1405916A1 (en) * 1997-02-21 2004-04-07 Isis Innovation Limited Recombinant vaccinia virus incapable of expressing the A41L gene
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2002080948A1 (en) * 2001-04-05 2002-10-17 The Trustees Of Princeton University Compositions and methods for treating inflammation and related conditions
WO2003005953A2 (en) * 2001-07-12 2003-01-23 Immunex Corporation Viral proteins capable of binding lar
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
AU2002330053A1 (en) * 2001-09-20 2003-04-01 Schering Corporation Chemokines as adjuvants of immune response
WO2004005892A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of California Antimicrobial activity of interferon-inducible elr chemokines
WO2004014314A2 (en) * 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
US20100189747A1 (en) * 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
WO2006076383A2 (en) * 2005-01-11 2006-07-20 Rosetta Stone Labs, Llc Composition and method for inducing a protective vaccine response
EP1933857A2 (en) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
CA2622772A1 (en) * 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
DE602007009954D1 (de) 2006-03-22 2010-12-02 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid-targets
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
WO2008149354A2 (en) 2007-06-04 2008-12-11 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of inflammatory diseases and methods of using same
WO2009082594A2 (en) * 2007-11-26 2009-07-02 Fox Chase Cancer Center Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT840615E (pt) 1995-04-19 2003-10-31 Robarts John P Res Inst Proteina de ligacao da quemoquina e metodos para a sua utilizacao
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
WO1998036766A1 (en) * 1997-02-21 1998-08-27 Isis Innovation Limited Anti-hiv protein
EP1405916A1 (en) * 1997-02-21 2004-04-07 Isis Innovation Limited Recombinant vaccinia virus incapable of expressing the A41L gene
JP2001168323A (ja) * 1999-12-06 2001-06-22 Mitsubishi Electric Corp 半導体装置の製造方法

Also Published As

Publication number Publication date
DE69834179D1 (de) 2006-05-24
US20020071849A1 (en) 2002-06-13
US7384643B2 (en) 2008-06-10
JP4191255B2 (ja) 2008-12-03
US6355252B1 (en) 2002-03-12
US20040142002A1 (en) 2004-07-22
EP0985046A1 (en) 2000-03-15
JP2001513629A (ja) 2001-09-04
ATE323170T1 (de) 2006-04-15
EP0985046B1 (en) 2006-04-12
EP1405916A1 (en) 2004-04-07
AU749921B2 (en) 2002-07-04
AU6302098A (en) 1998-09-09
WO1998037217A1 (en) 1998-08-27

Similar Documents

Publication Publication Date Title
AU749921B2 (en) A soluble vaccinia virus protein that binds chemokines
Alcami et al. A soluble receptor for interleukin-1β encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection
Mossman et al. Disruption of M-T5, a novel myxoma virus gene member of poxvirus host range superfamily, results in dramatic attenuation of myxomatosis in infected European rabbits
Symons et al. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity
KR100196204B1 (ko) 폭스비루스 성분의 조합에 기초한 파라뮤니티 유발인자, 그의 제조방법 및 그의 약제에의 이용
CA2218499C (en) Chemokine binding protein and methods of use therefor
DE69314754T2 (de) Vorläufer B-Zelle stimulierender Faktor
US20090136917A1 (en) Systems and methods for viral therapy
DE69330878T2 (de) Ligand für den c-kit-rezepten und verfahren zu seiner nutzung
DE69928556T2 (de) Immunmodulation mittels genetischer modifikation von dendritischen zellen und b-zellen
EP0886679B1 (de) Parapockenviren, die fremd-dna enthalten, ihre herstellung und ihre verwendung in impfstoffen
DE69933528T2 (de) Verfahren zur Cytokinproduktionn unter Verwendung eines Sendai Virus Expressionssystems
DE69331977T2 (de) Löslicher LDL-Rezeptor, seine Herstellung und Verwendung
AU2002301315B2 (en) A soluble vaccinia virus protein that binds chemokines
EP1181381B1 (de) Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus
DE60128950T2 (de) Immunmodulatorisches Protein abgeleitet vom Yaba-Affentumor-Virus
EP0616642B1 (de) Neue thrombininhibitorische proteine aus landblutegeln
DE69031735T2 (de) Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
DE69028658T2 (de) Proteine, Vakzine und Nucleinsäuren
DE69834938T2 (de) Granulozyten-kolonie-stimulierender faktor aus der katze
EP0656949A1 (en) Vaccinia virus b15r used in interleukin b1-involving condition
CH681081A5 (enExample)
DE69230561T2 (de) Aus t-lymphozyten gewonnener hämatopoietischer wachstumsfaktor und verfahren zu seiner verwendung
AU754225B2 (en) Chemokine binding protein and methods of use therefor
EP0858465A2 (de) Protein mit anti-tumorwirkung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee